Comparison of Effects of a Thrombin-Based Hemostatic Agent and Topical Tranexamic Acid on Blood Loss in Patients with Preexisting Thromboembolic Risk Undergoing a Minimally Invasive Total Knee Arthroplasty. A Prospective Randomized Controlled Trial

Table 3

Total blood loss and transfusion requirement (continuous data are presented as mean (standard deviation)).

Characteristics	TXA ()	Floseal® ()	Placebo ()	value
				TXA vs Floseal	TXA vs placebo	Floseal vs placebo
Wound length in extension (cm)	8.65 (0.87; 7-11)	8.76 (0.98; 7-12)	8.41 (0.82; 7-10)	0.882	0.552	0.298
Postoperative Hb level day 1 (g/dl)	11.79 (1.13; 9.6-14.1)	10.92 (1.16;8.6-12.9)	10.81 (1.03; 9.2-13.0)	0.007	0.002	0.916
Postoperative Hb level day 2 (g/dl)	10.94 (1.12; 8.6-13.9)	9.86 (1.24;8-12)	9.69 (1.08; 8-12)	0.001	<0.001	0.832
Postoperative Hb level day 3 (g/dl)	10.71 (1.03; 8.1-12.7)	9.50 (1.06; 7.8-11.5)	9.18 (0.97; 7.4-12.2)	<0.001	<0.001	0.417
Postoperative drainage volume(mL)	253 (98; 85-530)	370 (125; 160-720)	413 (149; 110-770)	0.001	<0.001	0.384
Blood transfusion (no./total no.) (%)	0/34 (0.0%)	3/34 (8.8%)	1/35 (2.9%)	0.220
Total blood loss (mL)	645 (209; 227-1090)	1145 (303; 535-1942)	1103 (305; 424-1711)	<0.001	<0.001	0.819
Length of hospital stay (days)	4.24 (0.50; 4-6)	4.24 (0.5; 3-5)	4.17 (0.45; 4-6)	1.000	0.860	0.860

TXA: tranexamic acid.